A blast came out from Medscape about the FDA updating warning labels on some drugs based on reports from doctors about problems. Most of the drugs involved are injectables or IV medications that most consumers wouldn’t have in their home.
The one item on the new list that caught my attention is the anti-epilepsy drug, Keppra. The warning label has been revised to include the risk of kidney damage (see chart below, which includes links to FDA pages).
This information was announced last week, and many of the websites that you trust for information (and the paper enclosed with pill bottles that you might have at home) may not have been updated with this new information.
If you take this medication, you might want to talk to your doctor.
Other drugs are under consideration for new warnings.
The details on the FDA’s Adverse Even Reporting System (FAERS) are here: https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/ucm070093.htm
The usual caveat applies. I’m not a doctor; I’m a researcher. My goal is to publish information that can help people make better decisions.
|Keppra (levetiracetam) tablets, for oral use
Keppra (levetiracetam) extended-release tablets, for oral use
Keppra (levetiracetam) oral solution
Keppra (levetiracetam) injection, for intravenous use
|Acute kidney injury and interstitialThe nephritis||The “Adverse Reactions; Postmarketing Experience” section of the labeling for Keppra and Keppra XR was updated to include acute kidney injury.|